Enveric Biosciences, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Enveric Biosciences, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $39.91M | Mar 25, 2020 |
| FY2019 | Dec 31, 2018 | $43.00M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $48.59M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $36.15M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $20.26M | Apr 4, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $39.91M | Aug 12, 2020 |
| FY2019 | Dec 31, 2018 | $43.00M | Aug 12, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $8.15M | Aug 12, 2020 |
| FY2019 | Dec 31, 2018 | $8.98M | Aug 12, 2020 |
| FY2018 | Dec 31, 2017 | $10.24M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $6.93M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $6.87M | Apr 4, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.77M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($9.57M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($17.29M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($18.47M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($48.98M) | Jun 9, 2023 |
| FY2021 | Dec 31, 2020 | ($6.86M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.41M) | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | ($16.90M) | Aug 12, 2020 |
| FY2018 | Dec 31, 2017 | ($9.07M) | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | ($2.78M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.77M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($9.63M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($16.45M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($27.42M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($64.62M) | Jun 9, 2023 |
| FY2021 | Dec 31, 2020 | ($5.62M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.30M) | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | ($7.15M) | Aug 12, 2020 |
| FY2018 | Dec 31, 2017 | ($10.90M) | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | ($5.38M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.78M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.84M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $7.25M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $8.03M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $4.79M | Jun 9, 2023 |
| FY2021 | Dec 31, 2020 | $174.1K | Mar 31, 2022 |
| FY2016 | Dec 31, 2016 | $55.1K | Apr 4, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $20.50M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $5.32M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.30M | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | $10.79M | Aug 12, 2020 |
| FY2018 | Dec 31, 2017 | $18.51M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $9.36M | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.14M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($7.73M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($14.09M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($17.15M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($11.46M) | Jun 9, 2023 |
| FY2021 | Dec 31, 2020 | ($3.89M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($647.9K) | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | ($2.57M) | Aug 12, 2020 |
| FY2018 | Dec 31, 2017 | ($2.74M) | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | ($2.70M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $5.2K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $584.2K | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $189.7K | Jun 9, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.10M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $3.08M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $4.30M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $19.55M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $26.72M | Jun 9, 2023 |
| FY2021 | Dec 31, 2020 | $4.10M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $108.8K | Apr 1, 2021 |
| FY2019 | Sep 30, 2019 | $29.79M | Aug 12, 2020 |
| FY2019 | Jun 30, 2019 | $27.00M | Aug 12, 2020 |
| FY2019 | Dec 31, 2018 | $29.64M | Aug 12, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $4.00M | Jun 9, 2023 |
| FY2022 | Dec 31, 2021 | $4.41M | Jun 9, 2023 |
| FY2021 | Dec 31, 2020 | $681.3K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.92M | Apr 1, 2021 |
| FY2019 | Sep 30, 2019 | $18.93M | Aug 12, 2020 |
| FY2019 | Jun 30, 2019 | $13.75M | Aug 12, 2020 |
| FY2019 | Dec 31, 2018 | $18.88M | Aug 12, 2020 |
| FY2018 | Dec 31, 2017 | $32.75M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $27.84M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $13.58M | Apr 4, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.18M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.59M | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $1.96M | Mar 27, 2026 |
| FY2024 | Dec 31, 2022 | $14.67M | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | $22.31M | Mar 26, 2024 |
| FY2022 | Dec 31, 2020 | $3.42M | Jun 9, 2023 |
| FY2021 | Dec 31, 2019 | ($1.81M) | Mar 31, 2022 |
| FY2019 | Sep 30, 2019 | $10.86M | Aug 12, 2020 |
| FY2019 | Jun 30, 2019 | $13.25M | Aug 12, 2020 |
| FY2020 | Dec 31, 2018 | ($65.5K) | Apr 1, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2021 | $1.59M | Mar 26, 2024 |
| FY2019 | Dec 31, 2019 | $13.73M | Aug 12, 2020 |
| FY2019 | Dec 31, 2018 | $13.73M | Aug 12, 2020 |
| FY2018 | Dec 31, 2017 | $21.90M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $17.09M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $3.47M | Apr 4, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($114.85M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($106.07M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($96.50M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($79.21M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($60.74M) | Jun 9, 2023 |
| FY2021 | Dec 31, 2020 | ($11.76M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($4.89M) | Apr 1, 2021 |
| FY2019 | Sep 30, 2019 | ($37.81M) | Aug 12, 2020 |
| FY2019 | Jun 30, 2019 | ($37.87M) | Aug 12, 2020 |
| FY2019 | Dec 31, 2018 | ($34.48M) | Aug 12, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $431.4K | Aug 12, 2020 |
| FY2019 | Dec 31, 2018 | $1.37M | Aug 12, 2020 |
| FY2018 | Dec 31, 2017 | $4.88M | Mar 26, 2019 |
| FY2018 | Dec 31, 2016 | $1.38M | Mar 26, 2019 |
| FY2017 | Dec 31, 2015 | $1.88M | Apr 2, 2018 |
| FY2014 | Dec 31, 2014 | $5.1K | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $249 | Mar 31, 2015 |
| FY2014 | Dec 31, 2012 | $1.4K | Mar 31, 2015 |
| FY2013 | Dec 31, 2011 | $18.2K | Mar 28, 2014 |
| FY2012 | Dec 31, 2010 | $1.1K | Feb 28, 2013 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2019 | $740.3K | Apr 1, 2021 |
| FY2018 | Dec 31, 2018 | $6.5K | Mar 26, 2019 |
| FY2018 | Dec 31, 2017 | $1.88M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $1.94M | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (36) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (228) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (121) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (13) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (103) | Jun 9, 2023 |
| FY2019 | Dec 31, 2019 | (2) | Aug 12, 2020 |
| FY2019 | Dec 31, 2018 | (20) | Aug 12, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Apr 4, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (36) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (228) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (121) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (13) | Mar 26, 2024 |
| FY2019 | Dec 31, 2019 | (2) | Aug 12, 2020 |
| FY2019 | Dec 31, 2018 | (20) | Aug 12, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Apr 4, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.06M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 56,501 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 182,625 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 2.08M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 651,921 | Jun 9, 2023 |
| FY2021 | Dec 31, 2020 | 10.10M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 5.31M | Apr 1, 2021 |
| FY2019 | Nov 25, 2019 | 62.80M | Aug 12, 2020 |
| FY2019 | Dec 31, 2018 | 1.69M | Aug 12, 2020 |
| FY2018 | Dec 31, 2017 | 18.16M | Mar 26, 2019 |